You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Kidney conditions
  5. Chronic kidney disease

Tolvaptan for treating autosomal dominant polycystic kidney disease

  • Technology appraisal guidance
  • Reference number: TA358
  • Published:  28 October 2015
  • Guidance
  • Tools and resources
  • Information for the public
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 The technology
  • 3 The company's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Appraisal Committee members, guideline representatives and NICE project team
  • 7 Sources of evidence considered by the Committee
  • Update information

Update information

December 2015: Factual accuracy changes made to the evidence (sections 3.53, 3.55 and 3.56) and considerations (sections 4.12, 4.13, 4.16 and 4.17).

ISBN: 978-1-4731-1485-2


Previous page 7 Sources of evidence considered by the Committee
Back to top